Oncolys BioPharma Faces Decreased Sales and Losses

Oncolys BioPharma, Inc. (JP:4588) has released an update.

Oncolys BioPharma Inc. reports a decrease in net sales by 50.2% and a significant operating loss for the first half of 2024 compared to the same period in 2023, with no dividends paid or forecasted. The company’s total assets decreased slightly, while the equity ratio increased to 74.7%. Oncolys has not provided a financial forecast for the end of the fiscal year, citing the difficulty of making reasonable estimates.

For further insights into JP:4588 stock, check out TipRanks’ Stock Analysis page.